1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: On May 2, 2019, we announced that our board of directors approved a $50.0 million share repurchase program with $30.0 million tobe utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased.
−Removed: No open market repurchases were made during the three-month period ended March 31, 2023, and this repurchase program was canceled in April 2023.
−Removed: On April 13, 2023, we announced the establishment of a share repurchase program for an aggregate purchase price equal to $20,000,000 to occur within twelve months from the date of the share repurchase program as follows:
−Removed: (i) the first $5,000,000 of which will be effected through an accelerated stock repurchase program with an investment bank commencing with the Company’s next open trading window, which will open on or before May 12, 2023, (ii) the second $5,000,000 of which to be purchased in the open market, and (iii) the remaining $10,000,000 of which to be purchased in the open market subject to positive cash flow. 
−Removed: This share repurchase program replaces the program that was announced in May 2019.
−Removed: Certificate of Incorporation of Anika Therapeutics, Inc.
−Removed: (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-14027) filed by the Registrant on June 6, 2018)
−Removed: Bylaws of Anika Therapeutics, Inc., effective as of June 6, 2018 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No.
−Removed: 001-14027) filed by the Registrant on June 6, 2018)
−Removed: Rule 13a-14(a)/15d-14(a) Certifications
−Removed: Certification of Dr.
−Removed: Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Actof 2002.
−Removed: Section 1350 Certifications
−Removed: Certification of Dr.
−Removed: Blanchard, and Michael Levitz, pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 as filed with the SEC on May 9, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:
−Removed: Condensed Consolidated Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022 (unaudited)
−Removed: Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2023 and March 31, 2022 (unaudited)
−Removed: Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2023 and March 31, 2022 (unaudited)
−Removed: Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and March 31, 2022 (unaudited)
−Removed: Notes to Condensed Consolidated Financial Statements (unaudited)
−Removed: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: Filed herewith.
−Removed: Furnished herewith.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: ANIKA THERAPEUTICS, INC.
−Removed: /s/ MICHAEL LEVITZ
−Removed: Michael Levitz
−Removed: Executive Vice President, Chief Financial Officer and Treasurer
−Removed: (Authorized Officer and Principal Financial Officer)
+Added: Under our equity compensation plans, and subject to the specific approval of the Compensation Committee of our Board of Directors, grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee.
+Added: During the three-month period ended June 30, 2023, there were no shares withheld to satisfy grantee tax withholding obligations on restricted stock award vesting events.
+Added: Following is a summary of stock repurchases for the three-month period ended June 30, 2023 (in thousands, except share and per share data):
+Added: Total Number of
+Added: Shares Withheld (1)
+Added: Price per Share
+Added: Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs
+Added: April 1 to 30, 2023
+Added: May 1 to 31, 2023
+Added: June 1 to 30, 2023
+Added: In April 2023, we agreed to establish a share repurchase program for an aggregate purchase price of $20.0 million.
+Added: Of the $20.0 million, the first $5.0 million is to be effected through an accelerated stock repurchase program, the second $5.0 million is to be purchased in the open market and the remaining $10.0 million is to be purchased in the open market subject to positive cash flow.
+Added: On May 12, 2023 the Company entered into an accelerated share repurchase agreement with Bank of America, N.A.
+Added: (“Bank of America”) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement”) to purchase $5.0 million of shares of its common stock.
+Added: During the second quarter of 2023, 158,983 shares were delivered to us, constituting the initial delivery of shares and representing 80% of the then estimated total number of shares expected to be repurchased under the ASR Agreement.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.